The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interference of amphiregulin and EGFRvIII expression with outcome of patients with squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab-docetaxel treatment.
I. Tinhofer
Research Funding - Merck Serono
K. F. Klinghammer
No relevant relationships to disclose
W. Weichert
No relevant relationships to disclose
M. Knoedler
Honoraria - Merck Serono
A. Stenzinger
No relevant relationships to disclose
T. C. Gauler
Honoraria - Merck Serono
V. Budach
Honoraria - Merck Serono
U. Keilholz
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono; Sanofi
Research Funding - Merck Serono